Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common and one of the most aggressive subtypes of non-Hodgkin’s lymphomas. Front-line therapy consists of chemotherapy in combination with anti-CD20 monoclonal antibody rituximab. Relapses after rituximab-based regimen have poor prognosis and call for new treatment options. Immunohistochemistry analysis of relapsed DLBCL often reveal.
Author supplied keywords
Cite
CITATION STYLE
APA
Vockova, P., Svaton, M., Karolova, J., Pokorna, E., Vokurka, M., & Klener, P. (2020). Anti-CD38 therapy with daratumumab for relapsed/ refractory CD20-negative diffuse large B-Cell lymphoma. Folia Biologica (Czech Republic), 66(1), 17–23. https://doi.org/10.14712/fb2020066010017
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free